石四药集团盐酸尼卡地平获批上市制剂原料药

财中社2025-03-05

3月5日，石四药集团（02005）发布公告，近日公司获得中国国家药品监督管理局批准，盐酸尼卡地平已登记为上市制剂使用的原料药。盐酸尼卡地平主要用于治疗高血压，此次批准标志着公司在产品开发方面取得了重要进展。　　公告的目的是为了让股东及潜在投资者了解公司的最新业务发展情况。此次批准将有助于公司进一步拓展市场，提高产品竞争力，促进公司未来的业绩增长。（文章来源：财中社）

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2517395954?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-05 12:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517395954","market":"hk","top_or_hot":-1,"title":"石四药集团盐酸尼卡地平获批上市制剂原料药","media":"财中社","content":"<div>\n<p>3月5日，石四药集团（02005）发布公告，近日公司获得中国国家药品监督管理局批准，盐酸尼卡地平已登记为上市制剂使用的原料药。盐酸尼卡地平主要用于治疗高血压，此次批准标志着公司在产品开发方面取得了重要进展。　　公告的目的是为了让股东及潜在投资者了解公司的最新业务发展情况。此次批准将有助于公司进一步拓展市场，提高产品竞争力，促进公司未来的业绩增长。（文章来源：财中社）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202503053337071017.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石四药集团盐酸尼卡地平获批上市制剂原料药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石四药集团盐酸尼卡地平获批上市制剂原料药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-05 12:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202503053337071017.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月5日，石四药集团（02005）发布公告，近日公司获得中国国家药品监督管理局批准，盐酸尼卡地平已登记为上市制剂使用的原料药。盐酸尼卡地平主要用于治疗高血压，此次批准标志着公司在产品开发方面取得了重要进展。　　公告的目的是为了让股东及潜在投资者了解公司的最新业务发展情况。此次批准将有助于公司进一步拓展市场，提高产品竞争力，促进公司未来的业绩增长。（文章来源：财中社）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202503053337071017.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02005","symbol_name":"石四药集团","start_time":0,"source_url":"http://finance.eastmoney.com/a/202503053337071017.html","article_id":"2517395954","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517395954","pubTimestamp":1741149308,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"3月5日，石四药集团（02005）发布公告，近日公司获得中国国家药品监督管理局批准，盐酸尼卡地平已登记为上市制剂使用的原料药。盐酸尼卡地平主要用于治疗高血压，此次批准标志着公司在产品开发方面取得了重要进展。公告的目的是为了让股东及潜在投资者了解公司的最新业务发展情况。此次批准将有助于公司进一步拓展市场，提高产品竞争力，促进公司未来的业绩增长。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02005":"石四药集团","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","BK1191":"制药"},"translate_title":"Shisi Pharmaceutical Group's nicardipine hydrochloride was approved for marketing as a raw material drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"3月5日，石四药集团（02005）发布公告，近日公司获得中国国家药品监督管理局批准，盐酸尼卡地平已登记为上市制剂使用的原料药。盐酸尼卡地平主要用于治疗高血压，此次批准标志着公司在产品开发方面取得了重要进展。　　公告的目的是为了让股东及潜在投资者了解公司的最新业务发展情况。此次批准将有助于公司进一步拓展市场，提高产品竞争力，促进公司未来的业绩增长。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517395954","isCrawlerRequest":true}